Navigation Links
Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
Date:10/22/2008

Clinical evidence continues to build for the company's key technologies

PRINCETON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a company specializing in advanced wound care, today announced that eleven clinical posters focusing on its new technologies have been accepted and will be presented at next week's Clinical Symposium on Advances in Skin & Wound Care in Las Vegas. The products featured include MEDIHONEY dressing with Active Leptospermum Honey, ALGICELL Ag Silver Antimicrobial dressing, and XTRASORB(TM) Super Absorbent dressing. The clinical posters review cases of hard-to-heal wounds of various etiologies, and depict how Derma Sciences' new technologies are helping to improve care for the elderly, patients with diabetes and vascular diseases, and immuno-compromised patients. This patient population, exceeding 70 million worldwide, sees great quality of life improvements when chronic wounds are healed faster and with fewer complications, and when infections are either prevented or cleared more quickly.

Clinical posters at wound conferences typically focus on cases involving difficult-to-heal wounds, and relate a clinician's perspective on how a given technology or methodology helped in the management of the condition. The posters are initially submitted as abstracts and are peer reviewed. If the abstract is accepted, a large poster showing before and after pictures of the case series -- along with detailed explanations as to the issues, rationales, methodologies, outcomes, and conclusions -- is created and is presented to the conference attendees as a part of the overall continuing education program. Four of the most recently completed and not previously announced posters featuring Derma Sciences' products include:

"Limb at Risk: Use of Active Leptospermum Honey for the management of an infected foot wound complicated by cellulitis." (MEDIHONEY(R))

Paul A. Ligouri, MD, Kim L. Peters, RN, CWS

Whittier Rehabilitation Hospital, Bradford, MA

"Active Leptospermum Honey: Treatment for various lower extremity dermatologic issues." (MEDIHONEY(R))

Tracey C. Vlahovic, DPM, associate professor, Eric Roberts, BS

Temple University School of Podiatric Medicine, Philadelphia, PA

"Management of an MRSA colonized wound using Active Leptospermum Honey impregnated calcium alginate." (MEDIHONEY(R) & XTRASORB(TM))

Mary Webb, RN, BSN, MA, CIC, Infection Control Practitioner

San Mateo Medical Center, San Mateo, CA

"A cost-effective alternative: Investigating absorbent gelling calcium alginate dressings with antimicrobial silver." (ALGICELL Ag(R))

Connie Johnson, RN, WCC, Care One, Madison, New Jersey

With regard to the clinical presentations at the Clinical Symposium, CEO Ed Quilty stated, "The interest in our products, led by MEDIHONEY(R), continues to increase. Given that advancing wound care is our stated goal, it is rewarding to see that eleven clinical posters on our products have been accepted for presentation at this highly regarded conference. The posters on MEDIHONEY do an excellent job showing the variety of wounds that can be managed with this versatile dressing. The poster on XTRASORB goes right to the heart of the issue with this dressing -- a patient was able to be discharged from the hospital due to his ability to easily change this super absorbent dressing at home. Previously, dressing changes were multiple times per day and required nursing assistance. We believe this dressing is going to help facilities save a great deal of money due to its benefits over conventional absorbent dressings. Lastly, as our sales of MEDIHONEY have increased, so have our sales of ALGICELL Ag. Connie Johnson's poster is a perfect example of how this cost-effective alternative enables clinicians to save money while maintaining a highly effective dressing regimen."

Quilty concluded, "As planned, our products are having a meaningful difference on the lives of patients with chronic and hard-to-heal wounds. The evidence supporting our new technologies is growing, as is our reputation in the field of advanced wound care."

The Clinical Symposium on Advances in Skin & Wound Care is an annual conference, held this year October 26-30, 2008, in Las Vegas. The goal of the 23rd annual event is to meet the continuing-education needs of multidisciplinary skin and wound care practitioners, from novice to expert, by providing a forum for educational sessions and interactive workshops that offer comprehensive wound management strategies. Over 1,100 multidisciplinary practitioners including nurses, physicians, podiatrists, physical therapists, dietitians and others who manage skin and wound care patients across the continuum of health care are expected to attend. For more information on the symposium, please go to http://www.symposiumonwoundcare.com.

The posters will be on display throughout the duration of the clinical symposium. Additional information can be obtained by calling Derma Sciences' customer service, at 800 445 7627.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermasciences.com

(609) 514-4744 Brian Kennedy (media)

brian@allencaron.com

(212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
6. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
9. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
10. Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications
11. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
Breaking Biology Technology:
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):